These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 33710976)

  • 41. Activity of Tedizolid in Methicillin-Resistant Staphylococcus aureus Experimental Foreign Body-Associated Osteomyelitis.
    Park KH; Greenwood-Quaintance KE; Mandrekar J; Patel R
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6568-6572. PubMed ID: 27550347
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro activity of tedizolid against gram-positive bacteria in patients with skin and skin structure infections and hospital-acquired pneumonia: a Korean multicenter study.
    Lee Y; Hong SK; Choi S; Im W; Yong D; Lee K
    Ann Lab Med; 2015 Sep; 35(5):523-30. PubMed ID: 26206690
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia model.
    Lepak AJ; Marchillo K; Pichereau S; Craig WA; Andes DR
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5916-22. PubMed ID: 22964254
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Use of linezolid susceptibility test results as a surrogate for the susceptibility of Gram-positive pathogens to tedizolid, a novel oxazolidinone.
    Zurenko G; Bien P; Bensaci M; Patel HN; Thorne G
    Ann Clin Microbiol Antimicrob; 2014 Sep; 13():46. PubMed ID: 25238753
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of tedizolid for the treatment of ventilated gram-positive hospital-acquired or ventilator-associated bacterial pneumonia in Japanese patients: Results from a subgroup analysis of a phase 3, randomized, double-blind study comparing tedizolid and linezolid.
    Mikamo H; Nagashima M; Kusachi S; Fujimi S; Oshima N; De Anda C; Takase A
    J Infect Chemother; 2022 Sep; 28(9):1235-1241. PubMed ID: 35718656
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Outpatient treatment of acute bacterial skin and skin structure infections (ABSSSI) with tedizolid phosphate and linezolid in patients in the United States: Subgroup analysis of 2 randomized phase 3 trials.
    De Anda C; Anuskiewicz S; Prokocimer P; Vazquez J
    Medicine (Baltimore); 2017 Dec; 96(52):e9163. PubMed ID: 29384903
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: safety summary.
    Das D; Tulkens PM; Mehra P; Fang E; Prokocimer P
    Clin Infect Dis; 2014 Jan; 58 Suppl 1():S51-7. PubMed ID: 24343833
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions.
    Flanagan S; Bartizal K; Minassian SL; Fang E; Prokocimer P
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3060-6. PubMed ID: 23612197
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens: REVIVE-1.
    Huang DB; O'Riordan W; Overcash JS; Heller B; Amin F; File TM; Wilcox MH; Torres A; Dryden M; Holland TL; McLeroth P; Shukla R; Corey GR
    Clin Infect Dis; 2018 Apr; 66(8):1222-1229. PubMed ID: 29281036
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of therapeutic and supratherapeutic doses of oral tedizolid phosphate on cardiac repolarisation in healthy volunteers: a randomised controlled study.
    Flanagan S; Litwin J; Fang E; Prokocimer P
    Int J Antimicrob Agents; 2016 Jul; 48(1):33-40. PubMed ID: 27342387
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Results of the surveillance of Tedizolid activity and resistance program: in vitro susceptibility of gram-positive pathogens collected in 2011 and 2012 from the United States and Europe.
    Sahm DF; Deane J; Bien PA; Locke JB; Zuill DE; Shaw KJ; Bartizal KF
    Diagn Microbiol Infect Dis; 2015 Feb; 81(2):112-8. PubMed ID: 25488274
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Characterization of Neurologic and Ophthalmologic Safety of Oral Administration of Tedizolid for Up to 21 Days in Healthy Volunteers.
    Fang E; Muñoz KA; Prokocimer P
    Am J Ther; 2017; 24(2):e227-e233. PubMed ID: 27941424
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of pharmacokinetic/pharmacodynamic systems analyses to inform dose selection of tedizolid phosphate.
    Lodise TP; Drusano GL
    Clin Infect Dis; 2014 Jan; 58 Suppl 1():S28-34. PubMed ID: 24343829
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vitro activities of tedizolid compared with other antibiotics against Gram-positive pathogens associated with hospital-acquired pneumonia, skin and soft tissue infection and bloodstream infection collected from 26 hospitals in China.
    Li S; Guo Y; Zhao C; Chen H; Hu B; Chu Y; Zhang Z; Hu Y; Liu Z; Du Y; Gui Q; Ji P; Zeng J; Cao B; Fu Q; Zhang R; Wang Z; Zhuo C; Feng X; Jia W; Jin Y; Xu X; Liao K; Ni Y; Yu Y; Xu X; Hu Z; Lei JE; Yang Q; Wang H
    J Med Microbiol; 2016 Oct; 65(10):1215-1224. PubMed ID: 27599998
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Radiolabeled Tedizolid Phosphate Liposomes for Topical Application: Design, Characterization, and Evaluation of Cellular Binding Capacity.
    Karpuz M; Atlihan-Gundogdu E; Demir ES; Senyigit Z
    AAPS PharmSciTech; 2021 Feb; 22(2):62. PubMed ID: 33528714
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In Vitro and In Vivo Activities of a Bi-Aryl Oxazolidinone, RBx 11760, against Gram-Positive Bacteria.
    Barman TK; Kumar M; Mathur T; Chaira T; Ramkumar G; Kalia V; Rao M; Pandya M; Yadav AS; Das B; Upadhyay DJ; Hamidullah ; Konwar R; Raj VS; Singh H
    Antimicrob Agents Chemother; 2016 Dec; 60(12):7134-7145. PubMed ID: 27645240
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics and Safety of Single Intravenous Doses of Ceftolozane/Tazobactam in Children With Proven or Suspected Gram-Negative Infection.
    Bradley JS; Ang JY; Arrieta AC; Larson KB; Rizk ML; Caro L; Yang S; Yu B; Johnson MG; Rhee EG
    Pediatr Infect Dis J; 2018 Nov; 37(11):1130-1136. PubMed ID: 30153232
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Surveillance of tedizolid activity and resistance: In vitro susceptibility of Gram-positive pathogens collected over 5 years from the United States and Europe.
    Bensaci M; Sahm D
    Diagn Microbiol Infect Dis; 2017 Feb; 87(2):133-138. PubMed ID: 27866673
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Skin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteers.
    Sahre M; Sabarinath S; Grant M; Seubert C; Deanda C; Prokocimer P; Derendorf H
    Int J Antimicrob Agents; 2012 Jul; 40(1):51-4. PubMed ID: 22584101
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetics of DA-7218, a new oxazolidinone, and its active metabolite, DA-7157, after intravenous and oral administration of DA-7218 and DA-7157 to rats.
    Bae SK; Yang SH; Shin KN; Rhee JK; Yoo M; Lee MG
    J Pharm Pharmacol; 2007 Jul; 59(7):955-63. PubMed ID: 17637190
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.